Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02048813CT.gov Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ibrutinib (this asset) | National Cancer Institute (NCI) | P3 | B · 60 |
| Epoetin Alfa | Mayo Clinic | P4 | BBB |
| Erythropoietin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Epoetin Beta | Institut du Cancer de Montpellier - Val d'Aurelle | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | BBB |
| Cyclophosphamide | OHSU Knight Cancer Institute | P4 | BBB |
| Darbepoetin Alfa | Amgen | P3 | BBB |
| Luspatercept | Guangdong Second Provincial General Hospital | P4 | BBB |
| Ferric Cation | National Cancer Center, Korea | P4 | BBB |
+42 more in the Anemia cohort
Other indications for Ibrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P4 | BBB · 72 |
| Waldenstrom Macroglobulinemia | — | P4 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Epoetin AlfaMayo ClinicBBB
- ErythropoietinSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- Epoetin BetaInstitut du Cancer de Montpellier - Val d'AurelleBBB
- Ferric Carboxymaltose [Ferinject]Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)BBB
- CyclophosphamideOHSU Knight Cancer InstituteBBB
Citation
Floatz Terminal. Ibrutinib in Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibrutinib-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →